At the dawn of a tense economic period, the French government is undertaking a major overhaul of public health policies. Citing a risk of exceeding expenditures, Catherine Vautrin, Minister of Health, announces a set of unprecedented measures aimed at optimizing savings while maintaining access to care. Among the proposed innovations, doubling the medical deductibles has sparked intense debate, while revising the rules governing sick leaves aims to make employers more responsible and limit perceived abuse. This action plan, which also includes a modification of the status of long-term conditions and a reflection on the reimbursements for thermal cures, reveals the complexity faced by the state in balancing healthcare interdependence and budgetary equilibrium. Key industries such as Sanofi, Pierre Fabre, and Biocodex are also involved in these adjustments, emphasizing the stakes intertwined between public health and industrial innovation. The government’s intent is part of a broader context of budgetary austerity, highlighting that the savings to be made exceed 5 billion euros by the end of next year, according to various official sources.
Medical deductibles: a controversial doubling to contain healthcare expenses
The government has highlighted the need to adjust medical deductibles to strengthen the health insurance budget. Currently set at €1 per box of medication and capped at €50 annually, these deductibles are expected to be doubled, with a monthly cap of €8. Catherine Vautrin justifies this measure as a revitalization of the principle of responsible cost sharing within the healthcare system.
This modification aims to curb excessive and sometimes reckless use of care, seen as a primary factor in the observed financial imbalance. Indeed, the minister expressed concern over the myth of unconditional “gratuitousness.” Furthermore, this change has generated mixed reactions among healthcare professionals and users, some warning of a risk of foregoing care, especially among vulnerable populations. However, the short-term impact of a larger deductible on individual behaviors remains difficult to measure.
Key points of the new deductible
- 💊 Current deductible: €1 per box, annual cap €50
- 💊 New proposal: doubling to €2 per box
- 📅 New monthly cap set at €8
- 📉 Goal: make insured individuals more responsible and reduce excessive use
| Type of deductible | Current amount (€) | Projected amount (€) | Frequency | Targeted effect |
|---|---|---|---|---|
| Medication deductible | €1 / box | €2 / box | Annual cap €50 → €100 | Encourage moderation in consumption |
| Monthly ceiling | None | €8 | Every month | Limit potential regular expenses |
It should be noted that this decision takes place in a context where several major pharmaceutical groups such as Sanofi, Pierre Fabre, and Merck are closely monitoring regulatory changes, fearing an indirect impact on drug prices and volumes. An in-depth analysis of the economic and social repercussions is already underway.
Management of sick leave: moving toward more rigorous restrictions and partial transfer to employers
The regulation of sick leave is central to the government’s strategy to contain expenditure overruns. One of the key innovations involves delaying the coverage of daily indemnity payments by health insurance from 4 to 7 days, thus transferring this burden to employers. This decision, perceived as a way to promote moderation, sparks lively debate among business leaders and unions.
The government also recommends limiting the maximum duration of initial sick leaves in general medicine to 15 days, compared to an unlimited period currently, and to one month for post-hospitalization discharges. This measure aims to combat certain “abuses” denounced in the sector, with detected fraud reaching 42 million euros in 2024, a significant rise compared to the previous year.
Strategic elements around sick leave
- 🔄 Transfer of the first 7 days of indemnities to employers
- ⏳ Maximum duration of first sick leave in general medicine: 15 days
- 🏥 Maximum duration post-hospitalization: 30 days
- 💰 Key figure: 42 million euros detected in fraud in 2024
| Measure | Current situation | Projected position | Expected impact |
|---|---|---|---|
| Coverage of sick leave indemnities | First 4 days by employer, then by health insurance | First 7 days covered only by employer | Reduction of abuse through employer responsibility |
| Duration of first sick leave | No limit (Unlimited initial leaves) |
Limited to 15 days in general medicine | To regulate the length of sick leaves |
Beyond the figures, the debate remains lively regarding the actual impact on employees’ health. Experts emphasize the risk of increased pressure on workers, potentially leading to undesired effects. This political choice is all the more critical as it resonates with issues raised by economic analyses from groups like Ipsen and Boehringer Ingelheim, which scrutinize the reform and its effect on healthcare consumption in the short and medium term.
Revision of thermal cure reimbursements and drugs with low medical usefulness (SMR)
Among the contemplated measures, revising the full reimbursement of thermal cures is debated. Currently reimbursed at 100%, they represent an annual cost of 350 million euros for health insurance, a significant budget item but relatively minor at the overall level, approximately 0.1% of the total budget. The government considers that these expenses could be better targeted, notably by entirely removing coverage for some drugs deemed to have low effectiveness.
The Court of Auditors, in its latest report, has also recommended ending the reimbursement for prescribed thermal cures, suggesting tightening criteria. This recommendation aligns with an intention to rationalize as expressed by the minister and echoed in specialized media such as Les Echos.
Summary of issues related to thermal cures
- 🏖️ Thermal cure: currently reimbursed at 100%
- 💸 Budget: about 350 million euros/year, or 0.1% of the health security budget
- ⚖️ Medical debate: clinical benefits vs. resting effect
- 📜 Recommendation: ending of reimbursement prescribed by general practitioners
| Aspect | Current situation | Government proposal | Presumed consequence |
|---|---|---|---|
| Reimbursement of thermal cures | 100% | Possible end of full reimbursement | Significant cost reduction for health insurance |
| Drugs with low SMR | Variable coverage | End of full reimbursement | Rationalization of expenses |
The positioning of companies such as Novartis or AbbVie could evolve depending on these changes, as the list of affected drugs may be regularly reviewed, impacting both markets and pharmaceutical research.
Long-term conditions (LTC): controlled exit to manage costs
Long-term conditions, which include severe pathologies benefiting from 100% reimbursement, are also in the government’s sights. The aim is now to cap reimbursements strictly for medications directly related to LTC and establish a controlled exit from the system when a patient’s health no longer requires this specific coverage.
This measure raises strong concerns among healthcare professionals, who fear excessive administrative management at the expense of patients. The key issue concerns the criteria for eligibility. The clinical complexity makes this a sensitive topic, especially since the risks associated with premature treatment cessation can be serious.
Requirements and principles for LTC
- 🩺 100% reimbursement limited to LTC-related medications
- 📋 Possible exit from the system in case of confirmed recovery
- ⚠️ Risks: clear criteria need to be defined to prevent misuse
- 🔬 Increased medical monitoring required
| Dimension | Current regime | Planned reform | Expected impact |
|---|---|---|---|
| Coverage of non-LTC medications | Reimbursed at 100% | Gradual removal of reimbursement | Cost rationalization |
| Exit from LTC system | Generally not automatic | Exit possible after medical assessment of recovery | Cost reduction in the medium term |
These decisions will be closely monitored by healthcare facilities, and it is worth noting that some, such as Ipsen, will participate in evaluating the relevant clinical criteria.
Mandatory vaccination in nursing homes: enhanced preventive health measure
As part of strengthening preventive measures, flu vaccination in nursing homes is becoming mandatory, with a coverage target of 95%, up from 85% currently. This requirement aims to protect a particularly vulnerable population and prevent overload of hospital services during the winter season.
The government emphasizes the importance of a preventive policy to reduce costs associated with secondary complications and preventable hospitalizations. This approach draws inspiration from practices in several European countries and studies highlighting the health and economic costs of seasonal epidemics.
Essential points of the vaccination policy in nursing homes
- 🏥 Mandatory flu vaccination in nursing homes
- 🎯 Coverage goal: 95% of residents
- 📉 Reduction of flu-related hospitalizations
- 💉 Reduction of healthcare costs in the medium term
| Current status | 2025 goal | Expected consequence | |
|---|---|---|---|
| Flu vaccination coverage in nursing homes | 85% | 95% | Improved resident health |
This measure is supported by health authorities’ recommendations and benefits from the tacit support of several laboratories such as L’Oréal (through its health-oriented subsidiaries) and Vilmorin, committed to promoting innovations related to public health and prevention.
Limitation of medical nomadism: ensuring consistent medical follow-up
Another issue highlighted by the government concerns “medical nomadism,” namely the multiplication of consultations without real added value. This practice, often motivated by a desire for multiple opinions, generates substantial costs and complicates the management of medical records. To address this, repeated unjustified consultations will now be less covered by health insurance.
This decision is part of a policy aimed at promoting continuity of care through shared medical records, a tool that facilitates coordination among healthcare professionals. The goal is to encourage quality and relevance in care while limiting unnecessary interventions.
Key measures against medical nomadism
- 🩺 Repeated consultation: limited coverage
- 🗂️ Strengthening the use of shared medical records
- ✅ Encouragement of regular follow-up by a primary care physician
- 💸 Reduction of costs associated with unnecessary consultations
| Before reform | Planned measure | Expected effect |
|---|---|---|
| Multiple consultations without coordination | Limited coverage beyond the second opinion | Reduction of unnecessary expenses |
| Little use of shared medical records | Mandatory promotion of shared records | Improved follow-up and medical exchanges |
Reactions of healthcare sector actors to government measures
Government announcements evoke various responses from industry players, medical professionals, and patient associations. Pharmaceutical companies such as Biocodex, Novartis, and AbbVie closely monitor regulatory changes, aware that these updates could significantly reshape pharmaceutical markets.
Furthermore, medical unions raise concerns about a potential decline in care quality, especially with the limitation of sick leave and reimbursement caps. Several organizations emphasize the need for a delicate balance between economic efficiency and patient support, warning that overly restrictive measures could lead to deferred costs, particularly through an increase in untreated complications.
Non-exhaustive list of notable positions
- 🏥 Pharmaceutical companies: caution and adaptation to new constraints
- 🩺 Healthcare professionals: vigilance to maintain care quality
- 👥 Patient associations: fear of giving up care
- 📊 Economists: mixed reception, call for rigorous impact monitoring
- 📝 Expected increase in supplementary health insurance contracts
- 💳 Rise in the share of direct expenses for users
- 🏥 Adaptation of insurance offers to the new regulatory framework
- 📉 Partial reduction of public deficit through these measures
- 📈 Target set at around 5.5 billion euros in savings
- ⚖️ Need for a balance between savings and care maintenance
- 🔍 Strengthened oversight of possible abuses
- 🤝 Call for collective and coordinated mobilization
- ❓ What does the doubling of medical deductibles imply for patients?
The annual cap increases from €50 to €100, with a monthly cap of €8. This means insured individuals will need to contribute more financially to medical expenses. - ❓ How will the limitation of sick leave affect employers?
Employers will cover the daily allowances for the first 7 days of absence, a measure intended to reduce abusive sick leaves. - ❓ Will thermal cures still be reimbursed?
A full reimbursement is being considered to end, particularly for prescriptions made by general practitioners, with the specific goal of reducing spending. - ❓ How will LTC be regulated?
Reimbursement will be limited to treatments directly related to LTC, and a discharge process will be implemented when the patient’s health no longer necessitates this specific coverage. - ❓ What is the reaction of healthcare professionals to these measures?
They express reservations, fearing a decline in care quality and increased pressure on patients.
| Actor | Position | Key argument |
|---|---|---|
| Pharmaceutical companies | Monitoring and adaptation | Impact on market and research |
| Medical unions | Caution and vigilance | Care quality threatened |
| Patient associations | Concern about giving up care | Potential access to care endangered |
| Economic experts | Balanced analysis | Importance of impact oversight |
This diversity of opinions illustrates the major issue of health policy in the country — finding a balance between budget constraints and social imperatives.
Potential impact on health insurance and household expenses
The new measures announced will also influence the supplementary health insurance sector. Doubling the medical deductibles and the limitation of sick leave could lead to an increase in requests for better-suited supplementary coverage to these increased constraints.
At the same time, it is worth noting that some sector companies, such as Ipsen or Biocodex, as well as players in pharmaceutical distribution like Boehringer Ingelheim, anticipate an evolution in insured individuals’ behavior, especially regarding healthcare use and membership in mutual insurance schemes. This dynamic could redistribute financial pressures among social security, supplementary insurers, and policyholders themselves.
Consequences for households and insurance companies
| Factor | Current situation | Projected consequence |
|---|---|---|
| Medical deductibles | Annual ceiling €50 | Ceiling doubled to €100 |
| Sick leaves | Indemnification starts at the 4th day | Indemnification postponed to the 7th day |
| Cost for insured | Limited | Expected increase in out-of-pocket expenses |
This transformation profoundly impacts the health insurance market. Several sources, including Aide BTS Assurance, have analyzed these new configurations as part of a series of studies on the upcoming impact of these measures.
Perspectives and challenges of the government’s health savings plan
Finally, all these measures reflect a strong determination by the executive branch to enforce renewed budget discipline. By combining efforts related to deductibles, sick leave regulation, LTC restrictions, and thermal reimbursement reforms, the targeted savings could reach unprecedented heights. Several experts and reports estimate that the expected savings could approach or even exceed 5.5 billion euros.
However, as with any major change, managing social and health risks remains central to discussions. The main challenge is to preserve the quality of the French health system while controlling costs. The government calls for decisive and coordinated action, acknowledging at the same time the potential resistance from multiple stakeholders and users.
Main issues and points of attention
| Measure | Expected savings | Identified risks | Proposed solutions |
|---|---|---|---|
| Doubling of medical deductibles | 1.2 billion euros | Forgone care | Information and modulation based on profile |
| Limitation of sick leave | 1.5 billion euros | Pressure on workers | Strict medical oversight |
| LTC reform | 1.0 billion euros | Medical misuse | Clear criteria and transparency |
| Reduction of thermal cure reimbursement | 0.8 billion euros | Professional opposition | Thorough communication |
To delve deeper into this information, see: France Info – Health Savings 2025, Aide BTS Assurance – Health savings measures, and Les Echos – Health savings plan 2025.
Frequently asked questions about the new health savings measures in 2025
Source: www.previssima.fr
Entraîne-toi avec nos Quiz de révision
Fini les lectures passives. Pour retenir les notions clés du BTS Assurance, teste-toi ! Inscris-toi pour recevoir 1 quiz par jour directement dans ta boîte mail.
